بدائل البحث:
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
clinical decrease » clinical disease (توسيع البحث), clinical case (توسيع البحث), linear decrease (توسيع البحث)
increase » increased (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
clinical decrease » clinical disease (توسيع البحث), clinical case (توسيع البحث), linear decrease (توسيع البحث)
increase » increased (توسيع البحث)
-
821
-
822
-
823
-
824
-
825
-
826
-
827
-
828
-
829
-
830
-
831
Volitional control frequency and intensity in VH (Kapsner-Smith et al., 2025)
منشور في 2025"…Group differences were tested with general linear models.</p><p dir="ltr"><b>Results: </b>No significant differences were found between people with and without HVDs on any of the measures. …"
-
832
-
833
-
834
-
835
-
836
-
837
-
838
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Background<p>Umbilical cord blood (UCB)-derived CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>low</sup> regulatory T cells (Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus (SLE). …"
-
839
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Background<p>Umbilical cord blood (UCB)-derived CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>low</sup> regulatory T cells (Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus (SLE). …"
-
840
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Background<p>Umbilical cord blood (UCB)-derived CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>low</sup> regulatory T cells (Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus (SLE). …"